Anti-CD3 drug keeps diabetes at bay

No drug has ever delayed islet cell destruction. Now that teplizumab has, the challenge turns to identifying eligible recipients for the treatment.
Somerville, Massachusetts

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Biotechnology 37, 1099-1101 (2019)

doi: 10.1038/d41587-019-00025-4

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.